Literature DB >> 17392725

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin.

G A Herman1, P P Stein, N A Thornberry, J A Wagner.   

Abstract

Dipeptidyl peptidase-4 (DPP-4) inhibitors represent a new class of oral antihyperglycemic agents to treat patients with type 2 diabetes. DPP-4 inhibitors improve fasting and postprandial glycemic control without hypoglycemia or weight gain. This article focuses on the physiology, clinical pharmacology, tolerability, and clinical utility of the DPP-4 inhibitor sitagliptin in the management of type 2 diabetes.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17392725     DOI： 10.1038/sj.clpt.6100167

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  42 in total

1.  Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males.

Authors:  Gary A Herman; Goutam C Mistry; Bingming Yi; Arthur J Bergman; Amy Q Wang; Wei Zeng; Li Chen; Karen Snyder; Jon L Ruckle; Patrick J Larson; Michael J Davies; Ronald B Langdon; Keith M Gottesdiener; John A Wagner
Journal:  Br J Clin Pharmacol       Date:  2011-03       Impact factor: 4.335

2.  Comparisons of the efficacy of glucose control, lipid profile, and β-cell function between DPP-4 inhibitors and AGI treatment in type 2 diabetes patients: a meta-analysis.

Authors:  Xiaoling Cai; Wenjia Yang; Lingli Zhou; Simin Zhang; Xueyao Han; Linong Ji
Journal:  Endocrine       Date:  2015-06-06       Impact factor: 3.633

3.  Efficacy and Tolerability of Sitagliptin Compared with Glimepiride in Elderly Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control: A Randomized, Double-Blind, Non-Inferiority Trial.

Authors:  Paul Hartley; Yue Shentu; Patricia Betz-Schiff; Gregory T Golm; Christine McCrary Sisk; Samuel S Engel; R Ravi Shankar
Journal:  Drugs Aging       Date:  2015-06       Impact factor: 3.923

4.  Synthesis of New DPP-4 Inhibitors Based on a Novel Tricyclic Scaffold.

Authors:  Carolin Schwehm; Jin Li; Hongmei Song; Xiao Hu; Barrie Kellam; Michael J Stocks
Journal:  ACS Med Chem Lett       Date:  2015-01-13       Impact factor: 4.345

5.  Exploring key orientations at protein-protein interfaces with small molecule probes.

Authors:  Eunhwa Ko; Arjun Raghuraman; Lisa M Perez; Thomas R Ioerger; Kevin Burgess
Journal:  J Am Chem Soc       Date:  2012-12-27       Impact factor: 15.419

6.  Management of type-2 diabetes mellitus in adults: focus on individualizing non-insulin therapies.

Authors:  Luigi Brunetti; Julie Kalabalik
Journal:  P T       Date:  2012-12

Review 7.  Emerging principles in protease-based drug discovery.

Authors:  Marcin Drag; Guy S Salvesen
Journal:  Nat Rev Drug Discov       Date:  2010-09       Impact factor: 84.694

Review 8.  Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.

Authors:  Larry K Golightly; Caitlin C Drayna; Michael T McDermott
Journal:  Clin Pharmacokinet       Date:  2012-08-01       Impact factor: 6.447

9.  Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers.

Authors:  Kyoung Soo Lim; Joo-Youn Cho; Bo-Hyung Kim; Jung-Ryul Kim; Hwa-Sook Kim; Dong-Kyu Kim; Sung-Ho Kim; Hyeon Joo Yim; Sung-Hack Lee; Sang-Goo Shin; In-Jin Jang; Kyung-Sang Yu
Journal:  Br J Clin Pharmacol       Date:  2009-12       Impact factor: 4.335

10.  Effect of ABCB1 polymorphisms and atorvastatin on sitagliptin pharmacokinetics in healthy volunteers.

Authors:  Christina L Aquilante; Michael F Wempe; Maha S Sidhom; Lisa A Kosmiski; Julie A Predhomme
Journal:  Eur J Clin Pharmacol       Date:  2013-02-14       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.